Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK and PD of SHR-2010 in Healthy Subjects
NCT05398510Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jun 2022
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in IgA nephropathy (IgAN) comparing SHR-2010 (IV/SC) with Placebo (IV/SC) (2 arms). Primary endpoint: Incidence of subjects with adverse events. Started Jun 2022; status: completed.
02
Drugs
SHR-2010
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT05398510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05398510.